Price T Rowe Associates Inc. MD Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Price T Rowe Associates Inc. MD trimmed its position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 49.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,735 shares of the biopharmaceutical company's stock after selling 160,933 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.35% of Corbus Pharmaceuticals worth $1,945,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Altium Capital Management LLC lifted its stake in shares of Corbus Pharmaceuticals by 97.4% during the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock valued at $4,543,000 after buying an additional 190,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in Corbus Pharmaceuticals by 769.4% in the 4th quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company's stock worth $1,641,000 after buying an additional 123,100 shares in the last quarter. HealthInvest Partners AB raised its holdings in Corbus Pharmaceuticals by 41.3% during the fourth quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company's stock valued at $1,188,000 after acquiring an additional 28,731 shares during the period. Jump Financial LLC purchased a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at about $339,000. Finally, Walleye Capital LLC lifted its position in shares of Corbus Pharmaceuticals by 49.4% in the fourth quarter. Walleye Capital LLC now owns 55,236 shares of the biopharmaceutical company's stock valued at $652,000 after acquiring an additional 18,273 shares in the last quarter. 64.64% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Trading Down 0.6%

CRBP traded down $0.04 during trading hours on Tuesday, hitting $7.12. The company's stock had a trading volume of 49,806 shares, compared to its average volume of 358,276. The stock has a market cap of $87.13 million, a price-to-earnings ratio of -1.52 and a beta of 3.19. The business's 50-day moving average price is $6.33 and its 200-day moving average price is $10.71. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $4.64 and a 12 month high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13). On average, analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 earnings per share for the current year.

Analyst Ratings Changes

CRBP has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday, March 6th. Oppenheimer lowered their target price on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. B. Riley reaffirmed a "buy" rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, May 7th. Finally, William Blair initiated coverage on shares of Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an "outperform" rating on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Corbus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $50.88.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.